David M. Goldenberg

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat et al. · New England Journal of Medicine · 2019 · 850 citations

Medicine, Oncology, Pharmacology +17

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

David M. Goldenberg, Frank H. DeLand, Euishin Kim et al. · New England Journal of Medicine · 1978 · 758 citations

Medicine, Nuclear Medicine, Oncology +17

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan et al. · Oncotarget · 2015 · 474 citations · Full text

Pharmacy, Immunology, Oncology +17

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond et al. · Journal of Clinical Oncology · 2017 · 409 citations

Medicine, Oncology, Pharmacology +12